Document is current
Any future updates will be listed below
-
Authors
Mikaeloff, Flora
Svensson Akusjärvi, Sara http://orcid.org/0000-0002-1086-5409
Ikomey, George Mondinde
Krishnan, Shuba
Sperk, Maike
Gupta, Soham http://orcid.org/0000-0003-1136-3010
Magdaleno, Gustavo Daniel Vega
Escós, Alejandra http://orcid.org/0000-0002-2990-7920
Lyonga, Emilia
Okomo, Marie Claire
Tagne, Claude Tayou
Babu, Hemalatha
Lorson, Christian L.
Végvári, Ákos http://orcid.org/0000-0002-1287-0906
Banerjea, Akhil C.
Kele, Julianna
Hanna, Luke Elizabeth
Singh, Kamal http://orcid.org/0000-0001-6153-8929
de Magalhães, João Pedro http://orcid.org/0000-0002-6363-2465
Benfeitas, Rui
Neogi, Ujjwal http://orcid.org/0000-0002-0844-3338
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2017-01330, 2018-06156 and 2021-01756)
- License Information
-
More Information
Article History
Received: 28 September 2021
Accepted: 16 December 2021
First Online: 11 January 2022
Competing interests
: C.L.L. is the co-founder and chief scientific officer for Shift Pharmaceuticals. The remaining authors declare no competing interests.
